Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma von Tannir, Nizar M., Forero-Torres, Andres, Ramchandren, Radhakrishnan, Pal, Sumanta K., Ansell, Stephen M., Infante, Jeffrey R., de Vos, Sven, Hamlin, Paul A., Kim, Stella K., Whiting, Nancy C., Gartner, Elaina M., Zhao, Baiteng, Thompson, John A.

Volltext

1407 Expanding the therapeutic index of MMAE-based antibody-drug conjugates (ADCs) with a novel linker system (LD343) von Liu, Haidong, Xiao, Yang, Wang, Guobao, Shen, Wanwan, Wang, Lei, Shang, Xiao, Zhao, Baiteng, Chen, Zhu

Volltext

1406 A novel PTK7-directed antibody-drug conjugate (ADC) PRO1107 demonstrated broad antitumor activity with a promising safety profile in preclinical models von Xiao, Yang, Wang, Lei, Liu, Haidong, Shen, Wanwan, Zhang, Lin, Han, Tae, Zhao, Baiteng, Chen, Zhu

Volltext

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors von Traynor, Anne M, Hewitt, Maureen, Liu, Glenn, Flaherty, Keith T, Clark, Jason, Freedman, Steven J, Scott, Boyd B, Leighton, Ann Marie, Watson, Patricia A, Zhao, Baiteng, O'Dwyer, Peter J, Wilding, George

Volltext

Cytoprotection of human endothelial cells from menadione cytotoxicity by caffeic acid phenethyl ester: The role of heme oxygenase-1 von Wang, Xinyu, Stavchansky, Salomon, Zhao, Baiteng, Bynum, James A., Kerwin, Sean M., Bowman, Phillip D.

Volltext

Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates von Han, Tae H, Zhao, Baiteng

Volltext

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia von Stein, Eytan M., Walter, Roland B., Erba, Harry P., Fathi, Amir T., Advani, Anjali S., Lancet, Jeffrey E., Ravandi, Farhad, Kovacsovics, Tibor, DeAngelo, Daniel J., Bixby, Dale, Faderl, Stefan, Jillella, Anand P., Ho, Phoenix A., O'Meara, Megan M., Zhao, Baiteng, Biddle-Snead, Charles, Stein, Anthony S.

Volltext

Abstract P196: Novel hydrophilic drug linkers enable exatecan-based antibody-drug conjugates with promising physiochemical properties and in vivo activity von Liu, Haidong, Wang, Lei, Gavrilyuk, Julia, Han, Tae, Zhao, Baiteng, Shang, Xiao

Volltext

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30‐Expressing Hematologic Malignancies von Li, Hong, Han, Tae H., Hunder, Naomi N., Jang, Graham, Zhao, Baiteng

Volltext

Geldanamycin treatment inhibits hemorrhage-induced increases in KLF6 and iNOS expression in unresuscitated mouse organs: role of inducible HSP70 von Kiang, Juliann G, Bowman, Phillip D, Wu, Brian W, Hampton, Nyasa, Kiang, Andrew G, Zhao, Baiteng, Juang, Yuang-Taung, Atkins, James L, Tsokos, George C

Volltext

Abstract 1759: PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma von Wang, Lei, Liu, Haidong, Shang, Xiao, Han, Tae, Zhao, Baiteng

Volltext

Application of scaling factors in simultaneous modeling of microarray data from diverse chips von ZHENLING YAO, BAITENG ZHAO, HOFFMAN, Eric P, GHIMBOVSCHI, Svetlana, DUBOIS, Debra C, ALMON, Richard R, JUSKO, William J

Volltext

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment von Zhao, Baiteng, Chen, Robert, O'Connor, Owen A., Gopal, Ajay K., Ramchandren, Radhakrishnan, Goy, Andre, Matous, Jeffrey V., Fasanmade, Adedigbo A., Manley, Thomas J., Han, Tae H.

Volltext

Abstract 2637: Novel folate receptor alpha-directed antibody-drug conjugate PRO1184 demonstrates broad antitumor activity with a promising safety profile in preclinical models von Wang, Lei, Liu, Haidong, Zhou, Chang, Han, Tae, Zhao, Baiteng, Chen, Zhu

Volltext

Abstract 1758: The preclinical pharmacology of PRO1102, a novel exatecan-based HER2-directed antibody-drug conjugate with robust anti-tumor activity von Wang, Lei, Liu, Haidong, Shang, Xiao, Han, Tae H., Zhao, Baiteng

Volltext

Abstract 1085: PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse carcinoma models von Zhao, Baiteng, Wang, Lei, Liu, Haidong, Huang, Suping, Shang, Xiao, Han, Tae

Volltext

Abstract DDT02-04: SGN-CD33A: Preclinical and phase 1 interim clinical trial results of a CD33-directed PBD dimer antibody-drug conjugate for the treatment of acute myeloid leukemi... von Kennedy, Dana A., Alley, Stephen C., Zhao, Baiteng, Feldman, Eric J., O'Meara, Megan, Sutherland, May

Volltext

Abstract 1405: Novel ADC platform delivers promising in vivo activity and safety von Liu, Haidong, Qi, Wenke, Wang, Lei, Wang, Guobao, Chen, Xinyue, Gavrilyuk, Julia, Han, Tae, Zhao, Baiteng, Shang, Xiao

Volltext

Abstract 4642: Model-based alternative clinical trial designs and evaluations for SGN-CD19A, a novel antibody-drug conjugate von Zhao, Baiteng, Albertson, Tina M., Law, Che-Leung, O'Meara, Megan M., Kostic, Ana, Han, Tae H.

Volltext

Abstract DDT01-04: SGN-CD19A: A novel Anti-CD19 antibody drug conjugate von Albertson, Tina M., Sandalic, Lali, Zhao, Baiteng, Kostic, Ana, Law, Che-Leung

Volltext